Thymosin Alpha-1 (Thymalfasin) Pregnancy and Lactation Safety
From the public record
Registered clinical studies of thymalfasin in pregnancy
ClinicalTrials.gov lists 3 registered studies that name thymalfasin as an intervention and list pregnancy as a condition, as of 2026-11-11. Of these, 1 are recruiting, 2 are completed and 0 are phase 3 studies.
| Measure | Value |
|---|---|
| Registered studies | 3 |
| Recruiting now | 1 |
| Not yet recruiting | 0 |
| Completed | 2 |
| Terminated, withdrawn or suspended | 0 |
| Phase 3 (including phase 2/3) | 0 |
| Phase 2 (including phase 1/2) | 2 |
| Phase 1 | 1 |
How this was calculated
Searched ClinicalTrials.gov for studies naming the drug as an intervention with the stated filter, downloaded every matching record and counted by status and phase. Combined phases are counted under the higher phase.
Studies whose intervention field matches thymalfasin and that list pregnancy as a condition, all statuses
A registered study is not a result. Counts include studies where the drug is a comparator or background treatment, and studies that never finished or reported. The filter relies on how each study was registered.
At a glance
- Pregnancy, Zadaxin label (Italy) / Contraindicated [1]
- Breastfeeding, Zadaxin label (Italy) / Contraindicated [1]
- US approval status / Not FDA-approved; no US pregnancy or lactation labeling [1]
- Milk transfer / The amount in human milk has not been reported [1]
- Half-life in blood / About 1.8 to 2.6 hours in healthy volunteers [2][1]
- Time to peak / About 0.7 to 2 hours after a subcutaneous dose [2][1]
What does the Zadaxin label say?
Zadaxin is the finished 1.6 mg thymalfasin injection sold outside the United States; it is not interchangeable with bulk thymosin alpha-1 powder [1]. The Italian label says it is not for children, is contraindicated in pregnancy and breastfeeding, and calls for caution in people with allergies or autoimmune disease and with other immune-modulating drugs [1]. The labeled regimen is 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first influenza vaccination, then repeated from week 8 to week 12 at the second vaccination [1].
Is there US pregnancy or lactation labeling?
No. A Drugs@FDA search returns no US application for thymosin alpha-1 [1]. FDA's December 2024 review notes four US orphan drug designations, but orphan designation is a separate process from approval and does not create a label [1]. The drug therefore has no FDA pregnancy or lactation labeling in the United States [1].
Does the immune mechanism matter in pregnancy?
Thymosin alpha-1 is described as an immune modulator that augments T-cell function [2]. It modulates signals delivered through innate immune receptors on dendritic cells, which affects T-helper effector and regulatory responses [5]. These mechanisms do not establish what effect it has on pregnancy outcomes.
Does it cross the placenta or enter breast milk?
Drugs taken in pregnancy generally reach the fetal circulation to some degree by passive diffusion, and placental enzymes and transporters modify how much gets through [7]. For thymosin alpha-1, transfer across the placenta is not established, and its concentration in human milk has not been reported [1].
What is known is how fast it clears. In healthy volunteers after subcutaneous injection it peaks at about 0.7 to 2 hours and has a half-life of about 1.8 to 2.6 hours, with no accumulation after daily dosing for five days [2][1]. An earlier pharmacy review put the serum half-life at about 2 hours, with blood levels back to baseline within 24 hours [2]. These figures describe clearance from the blood, not how much reaches a fetus or a nursing infant.
What about fertility?
Fertility effects of thymosin alpha-1 are not established. The 2026 Cochrane review of thymosin alpha-1 pooled 10 randomized trials in adults with chronic hepatitis B [9].
What is known about safety outside pregnancy?
FDA's search of its adverse-event database, run on April 22, 2024, returned zero reports for thymosin alpha-1 [1]. Authors tied to the manufacturer report more than 4,400 people enrolled in trials and more than 17 million doses of Zadaxin given after marketing, with adverse experiences described as 'infrequent and mild' [1].
The 2026 Cochrane review found that thymosin alpha-1 may have caused fewer serious adverse events than the comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) and fewer non-serious adverse events (risk ratio 0.47, 95% CI 0.27 to 0.83; very low-certainty evidence) [9]. Those figures come from hepatitis B trials, and the manufacturer-linked figures from trials and post-marketing use; neither addresses pregnancy or breastfeeding.
The short answer
The Italian Zadaxin label contraindicates thymosin alpha-1 in pregnancy and breastfeeding, and in the United States the peptide is not FDA-approved, so no US pregnancy or lactation labeling exists [1]. Its blood half-life is short, roughly 1.8 to 2.6 hours [2][1], but that figure does not tell us how much reaches a fetus or a nursing infant.
Frequently asked questions
Can I use thymosin alpha-1 while pregnant?
Does thymosin alpha-1 get into breast milk?
Why is there no FDA pregnancy labeling for thymosin alpha-1?
How long does thymosin alpha-1 stay in the body?
Is thymosin alpha-1 FDA-approved?
References
Show all 9 referencesHide references
- U.S. Food and Drug Administration.
- Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58(10):879-85; quiz 886-8.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- Pierluigi B, D'Angelo C, Fallarino F, Moretti S, Zelante T, Bozza S, et al. Thymosin alpha1: the regulator of regulators?. Ann N Y Acad Sci. 2010;1194:1-5.
- Raghupathy R. Th1-type immunity is incompatible with successful pregnancy. Immunol Today. 1997;18(10):478-82.
- Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet. 2004;43(8):487-514.
- . ACOG Committee Opinion No. 762: Prepregnancy Counseling. Obstet Gynecol. 2019;133(1):e78-e89.
- Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026;9(9):CD014610.